ALN-2232 (ACVR1C) Investigational RNAi therapy targeting ACVR1C in adipose tissue, undergoing Phase 1 clinical development for obesity and weight management.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-2232 (ACVR1C).
Add it to your Products I use list and share why you use it.